6975-75-3
6975-75-3
Chemical Structure
ILK-IN-3
- CAS. Nr.: 6975-75-3
- Formula:C10H12N6O
- Molecular Weight:232.24
IUPAC Name: (E)-4-((4-methoxyphenyl)diazenyl)-1H-pyrazole-3,5-diamine
InChIKey: QNRNTYHAOBVOKW-BUHFOSPRSA-N
SMILES: NC1=NNC(N)=C1/N=N/C2=CC=C(OC)C=C2
Biological Activity: ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model[1][2].
| Art. -Nr. | Produktname | Reinheit | Beschreibung | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ILK-IN-3 | 99.62% | ILK-IN-3 is an orally active integrin linked kinase (ILK) inhibitor. ILK-IN-3 improves the anticancer efficacy of Docetaxel (HY-B0011) in orthotopic LCC6 model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Jessica Kalra, et al. Validating the Use of a Luciferase Labeled Breast Cancer Cell Line, MDA435LCC6, as a Means to Monitor Tumor Progression and to Assess the Therapeutic Activity of an Established Anticancer Drug, Docetaxel (Dt) Alone or in Combination With the ILK Inhibitor, QLT0267. Cancer Biol Ther. 2011 May 1;11(9):826-38. [Content Brief]
- [2]. Mavrogeni ME, et al. A facile consensus ranking approach enhances virtual screening robustness and identifies a cell-active DYRK1α inhibitor. Future Med Chem. 2018 Oct;10(20):2411-2430. [Content Brief]
Keywords
